|
Type |
Source |
| 3 |
Revue |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 23 |
Revue |
Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP.
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection.
Am J Health-Syst Pharm 1997 ; 54: 1065-1068. |
| 25 |
Revue |
McGuire TR, Narducci WA, Fox JL.
Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1410-1414. |
| 27 |
Revue |
Chin A, Moon YSK, Chung KC, Gill MA.
Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days.
Am J Health-Syst Pharm 1996 ; 53: 1174-1176. |
| 28 |
Revue |
Lau DWC, Law S, Walker SE, Iazzetta J.
Dexamethasone phosphate stability and contamination of solutions stored in syringes.
PDA J Pharm Sci Technol 1996 ; 50: 261-267. |
| 29 |
Revue |
Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C.
Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions.
J Pharm Sci 1995 ; 84: 267-268. |
| 30 |
Revue |
Hagan RL, Mallett MS, Fox JL.
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days.
Am J Health-Syst Pharm 1996 ; 53: 1431-1435. |
| 57 |
Revue |
Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304. |
| 62 |
Revue |
Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125. |
| 63 |
Revue |
Marquardt Ed, Lam SSY.
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 811-812. |
| 73 |
Revue |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Revue |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Revue |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 85 |
Revue |
Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719. |
| 91 |
Revue |
Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210. |
| 99 |
Revue |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 132 |
Revue |
Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184. |
| 150 |
Revue |
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35. |
| 169 |
Revue |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 176 |
Revue |
Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
| 186 |
Revue |
Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
| 215 |
Revue |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Revue |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 253 |
Revue |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 266 |
Revue |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 280 |
Revue |
Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
| 288 |
Revue |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 300 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Revue |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Revue |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 316 |
Revue |
Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613. |
| 317 |
Revue |
Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 334 |
Revue |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Revue |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 |
Revue |
Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 |
Revue |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 389 |
Revue |
Walker SE, DeAngelis C, Iazzetta J, Eppel JG.
Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride.
Am J Hosp Pharm 1991 ; 48: 2161-2166. |
| 397 |
Revue |
Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126. |
| 479 |
Revue |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 491 |
Revue |
Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184. |
| 492 |
Revue |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Revue |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 546 |
Revue |
Lugo RA, Nahata MC.
Stability of diluted dexamethasone sodium phosphate injection at two temperatures.
Ann Pharmacotherapy 1994 ; 28: 1018-1019. |
| 660 |
Revue |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 730 |
Revue |
Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943. |
| 905 |
Revue |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 992 |
Revue |
Beijnen JH, Koks CHW.
Visual compatibility of ondansetron and dexamethasone.
Ann Pharmacotherapy 1991 ; 25: 869. |
| 1026 |
Revue |
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1057 |
Revue |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1072 |
Revue |
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
| 1200 |
Revue |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1201 |
Revue |
Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922. |
| 1232 |
Revue |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1259 |
Revue |
Jhunjhunwala VP, Bhalla HL.
Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection.
Am J Hosp Pharm 1981 ; 38: 900-901. |
| 1410 |
Revue |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Revue |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1496 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1633 |
Revue |
Walker SE, Law S.
Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions.
Can J Hosp Pharm 2002 ; 55: 27-38. |
| 1637 |
Revue |
Wong AH, Law S, Walker SE, Bowles SK.
Concentration-dependant compatibility and stability of dexamethasone and midazolam.
Can J Hosp Pharm 2000 ; 53: 24-31. |
| 1662 |
Revue |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1701 |
Revue |
Gupta VD.
Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes.
Int J Pharm Compound 2002 ; 6: 395-397. |
| 1712 |
Revue |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Revue |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Revue |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1803 |
Revue |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1866 |
Revue |
Vermeire A, Remon JP.
Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone.
Int J Pharm 1998 ; 174: 157-177. |
| 1901 |
Revue |
Good PD, Schneider JJ, Ravenscroft PJ.
The compatibility and stability of midazolam and dexamethasone in infusion solutions.
J Pain Symptom Manage 2004 ; 27, 5: 471-475. |
| 1925 |
Revue |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1932 |
Revue |
Trissel LA, Zhang Y.
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.
Int J Pharm Compound 2004 ; 8,5: 398-403. |
| 1953 |
Revue |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1971 |
Revue |
Azuara ML, Sanchez Y, Reyes R, Barcia E.
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Support Care Cancer 2001 |
| 1974 |
Revue |
Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
| 1982 |
Revue |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2022 |
Revue |
Watson DG, Lin M, Morton A, Cable CG, McArthur DA.
Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes.
J Pain Symptom Manage 2005 ; 30: 80-86. |
| 2087 |
Revue |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2090 |
Revue |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2109 |
Revue |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2125 |
Revue |
Gardiner PR.
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.
Hospital Pharmacist 2003 ; 10: 354-361. |
| 2132 |
Revue |
Anderson Collin R, Halford Zachery, MacKay Mark.
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes.
Int J Pharm Compound 2015 ; 19, 4 : 344-347. |
| 2205 |
Revue |
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E.
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Arzneimittel Forschung 2006 ; 56, 10: 714-720. |
| 2211 |
Revue |
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B.
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
J Clin Pharm Ther 2007 ; 32: 441-444. |
| 2239 |
Revue |
Wang C, Zhang X, Liu HY.
Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry.
Chinese J New Drugs 2005 ; 14, 2: 189-191. |
| 2262 |
Revue |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Revue |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2335 |
Revue |
Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729 |
| 2841 |
Revue |
Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV.
Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%.
Atencion Pharmaceutica 2009 ; 11, 3: 161-166. |
| 2900 |
Revue |
Hines S, Pleasance S.
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.
EJHP 2009 ; 15, 5: 32-38. |
| 3012 |
Revue |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3174 |
Revue |
Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM.
Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration.
Ann Pharmacotherapy 2011 ; 45: 130-131. |
| 3184 |
Laboratoire |
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005 |
| 3216 |
Revue |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Revue |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Revue |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3408 |
Revue |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3459 |
Revue |
Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513. |
| 3545 |
Laboratoire |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009 |
| 3564 |
Laboratoire |
Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3571 |
Revue |
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47. |
| 3577 |
Laboratoire |
Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit
Galen Limited |
| 3588 |
Laboratoire |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
Sandoz 2011 |
| 3604 |
Laboratoire |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3644 |
Laboratoire |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3646 |
Laboratoire |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2013 |
| 3668 |
Laboratoire |
Dexamethasone - Summary of Product Characteristics
Hospira 2015 |
| 3766 |
Revue |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Revue |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3779 |
Revue |
Kintzel P.E, Zhao T, Wen B, Sun D.
Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection
Am J Health-Syst Pharm 2014 ; 71:2061-2065 |
| 3824 |
Revue |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
Poster |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3838 |
Laboratoire |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 3925 |
Revue |
Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L.
Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C.
Ann Pharm Fr 2016 ; 75, 1 : 30-39. |
| 3927 |
Revue |
Wu G,Yeung S,Chen F.
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate.
Int J Pharm Compound 2017 ; 21, 1 : 66-75. |
| 3964 |
Revue |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 3967 |
Revue |
Staven V, Herra I, Wang S, Grönlie I,Tho I.
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.
J Pharm Pharmacol 2017 ;69,7:448-462 |
| 3976 |
Revue |
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
| 3981 |
Revue |
He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D.
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
EJHP 2017 ;24:162?166 |
| 4055 |
Revue |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4062 |
Revue |
Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection.
Int J Pharm Compound 2018 ;22,1:76-85 |
| 4145 |
Revue |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4154 |
Laboratoire |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4301 |
Revue |
Fang B-X, Chen F-C, Zhu D, Guo J, Wang L-H.
Stability of azasetron-dexamethasone mixture for chemotherapyinduced nausea and vomiting administration.
Oncotarget 2017 ;8, 63: 106249-106257. |
| 4310 |
Revue |
Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16. |
| 4319 |
Revue |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4389 |
Revue |
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213 |
| 4404 |
Poster |
Müller U, Haller F, Wiedemeier P, Steuer C.
Compatibility studies of seven commonly used drugs for parenteral administration in palliative care.
JFSPH 2019 2019 |
| 4428 |
Revue |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
| 4433 |
Revue |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4528 |
Revue |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4602 |
Revue |
Buga I, Uzoma J.I, Reindel K, Rashid K, Diep T, McCartan P, Zhao F.
Physical and Chemical Stability of Dexamethasone Sodium Phosphate in Intravenous Admixtures Used to Prevent Chemotherapy-Induced Nausea and Vomiting.
Hosp Pharm 2021 ; 56, 4: 215-220. |
| 4603 |
Revue |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4742 |
Revue |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4776 |
Revue |
Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A.
Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures.
Pharmaceutics 2023 ; 15: 2143. |
| 4801 |
Revue |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
